At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 182 enrolled
Drug / intervention
GSK 249553 vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection
In Brief
A Phase 2 clinical trial evaluating GSK 249553 vaccine and Placebo for Lung Cancer, Non-Small Cell. Completed, enrolled 182 participants across 62 sites in 14 countries.
Detailed Summary
Patients will receive injections of GSK 249553 vaccine . Appropriate tests will be performed to assess the safety of the treatment and its ability to induce an immune response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Non-Small Cell
Countries, Belgium, Estonia, Finland, France, Germany, Greece, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2002
First PostedFeb 2006
Primary CompletionJul 2011
TodayJul 2026
First PostedFeb 13, 2006
Enrollment StartMay 28, 2002
Primary CompletionJul 19, 2011
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 20.4 years ago
Interventions
GSK 249553 vaccinebiological
Intramuscular injection, 13 doses
Placebobiological
Intramuscular administration, 13 doses